VFA Patient Safety and Efficacy Evidence Partnership for Investigational Therapies

The vision

This VFA proposal would build on a mechanism already present in each record: federally connected clinical research that gathers and reviews patient safety and efficacy evidence for investigational therapies. The ALS bill would require review of enrollment, safety, and efficacy data for grant renewals and prompt reporting of unexpected serious adverse events. The medical marijuana order would direct expanded research on benefits, adverse events, interactions, and dosing to guide patients and doctors. The serious mental illness order would expand clinical trial participation, real-world evidence generation, and data sharing to support timely regulatory evaluation. The common VFA idea would make those duties comparable.

The constitutional backbone is direct. Article I, Section 9, Clause 7 provides that no money shall be drawn from the Treasury except through appropriations made by law, so any federal research coordination proposed here would operate only as authorized and funded by Congress. Related review and scheduling steps would remain governed by their existing statutes, including the Federal Food, Drug, and Cosmetic Act and the Controlled Substances Act procedures. This proposal would not approve a product, create access to an investigational drug, alter eligibility rules, or predetermine scheduling. It would add structure, public reporting, privacy protections, and time limits around evidence the government already seeks.

A principled conservative would gain fiscal discipline, clear legal boundaries, and no new entitlement to unapproved treatment: every activity would cite authority, remain subject to appropriations, and sunset unless reauthorized after evaluation. A good-faith progressive would gain stronger patient protections, better information for underserved patients and veterans, and public aggregate evidence on risks and benefits. The strongest objection is that uniform evidence rules could burden promising research; the answer is narrow, phased duties, published methods, independent evaluation of burden and data quality, and preservation of existing approval and access standards.